The Efficacy and Safety of Semaglutide-Based Medications for Long-Term Weight Loss and Cardiovascular Health
Semaglutide for Weight Loss and Cardiovascular Health
DOI:
https://doi.org/10.54393/pjhs.v6i4.2541Keywords:
Weight Loss, Cardiovascular Health, Semaglutide, ObesityAbstract
The advantages of semaglutide associated with weight loss have been well documented. However, its utilization regarding clinical safety and efficacy in treating obesity and Cardiovascular Health (CVH) conditions is less described. Objective: To focus on evaluating the effectiveness and safety of semaglutide-based medications for long-term weight loss and CVH. Methods: PubMed, Google Scholar, Cochrane Library, Scopus, and Clinical Trial. Gov. was systematically explored to undertake a detailed search of relevant papers from January 2015 to February 2024. Following PRISMA guidelines 1500 papers were identified initially, of which 500 papers were screened for their titles and abstracts, leading to a screening of eligibility of 200 full-text papers. Finally, 22 studies were further evaluated based on inclusion, and exclusion criteria, relevant data was gathered, and a systematic review was performed. Results: The results highlight the substantial contribution of semaglutide to clinically meaningful weight reduction among individuals with obesity. Overweight participants with semaglutide compared to other AOMs showed improved clinical efficacy and safety for sustainable weight loss, healthy BMI, and CV-related factors such as improvements in blood pressure, lipid profile, and risk factors. Conclusions: Semaglutide-based medicines not only are safe in clinical terms, but also work well for people with obesity, assisting them to reduce their weight in the long term while enhancing conditions of cardiovascular health. Results show benefits in terms of BMI, BP and lipid profiles thereby indicating that semaglutide may serve as a valuable, sustainable intervention for managing obesity and associated cardiovascular risks.
References
Lin X and Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Frontiers in endocrinology. 2021 Sep; 12: 706978. doi: 10.3389/fendo.2021.706978. DOI: https://doi.org/10.3389/fendo.2021.706978
Apovian CM. Obesity: definition, comorbidities, causes, and burden. American Journal of Managed Care. 2016 Jun; 22(7 Suppl): s176-85.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine. 2023 Apr; 33(3): 159-66. doi: 10.1016/j.tcm.2021.12.008. DOI: https://doi.org/10.1016/j.tcm.2021.12.008
Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. Journal of the American Medical Association. 2023 Nov; 330(20): 2000-15. doi: 10.1001/jama.2023.19897. DOI: https://doi.org/10.1001/jama.2023.19897
Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obesity Reviews. 2019 Jun; 20(6): 805-15. doi: 10.1111/obr.12839. DOI: https://doi.org/10.1111/obr.12839
Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May; 143(21): e984-1010. doi: 10.1161/CIR.0000000000000973. DOI: https://doi.org/10.1161/CIR.0000000000000973
Smits MM and Van Raalte DH. Safety of semaglutide. Frontiers in endocrinology. 2021 Jul; 12: 645563. doi: 10.3389/fendo.2021.645563. DOI: https://doi.org/10.3389/fendo.2021.645563
Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism. 2023 Jan; 25(1): 18-35. doi: 10.1111/dom.14863. DOI: https://doi.org/10.1111/dom.14863
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022 Oct; 28(10): 2083-91. doi: 10.1038/s41591-022-02026-4. DOI: https://doi.org/10.1038/s41591-022-02026-4
Qin W, Yang J, Deng C, Ruan Q, Duan K. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial. Diabetes, Obesity and Metabolism. 2024 Mar; 26(3): 911-23. doi: 10.1111/dom.15386. DOI: https://doi.org/10.1111/dom.15386
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in endocrinology. 2019 Apr; 10: 155. doi: /10.3389/fendo.2019.00155 DOI: https://doi.org/10.3389/fendo.2019.00155
Novograd J, Mullally J, Frishman WH. Semaglutide for weight loss: was it worth the weight?. Cardiology in Review. 2022 Nov; 30(6): 324-9. doi: 10.1097/CRD.0000000000000430. DOI: https://doi.org/10.1097/CRD.0000000000000430
Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2022 Sep; 13: 935823. doi: 10.3389/fphar.2022.935823. DOI: https://doi.org/10.3389/fphar.2022.935823
Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. Journal of the ASEAN Federation of Endocrine Societies. 2022 Aug; 37(2): 65. doi: 10.15605/jafes.037.02.14. DOI: https://doi.org/10.15605/jafes.037.02.14
Tzoulis P, Batavanis M, Baldeweg S. A real-world study of the effectiveness and safety of semaglutide for weight loss. Cureus. 2024 May; 16(5). doi: 10.7759/cureus.59558. DOI: https://doi.org/10.7759/cureus.59558
Zhang R, Hou QC, Li BH, Deng L, Yang YM, Li TX et al. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2023 Jun; 14: 1132004. doi: 10.3389/fendo.2023.1132004. DOI: https://doi.org/10.3389/fendo.2023.1132004
Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. Journal of the American Medical Association Network Open. 2022 Sep; 5(9): e2231982-. doi: 10.1001/jamanetworkopen.2022.31982. DOI: https://doi.org/10.1001/jamanetworkopen.2022.31982
Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. Journal of Pharmacy Technology. 2022 Aug; 38(4): 239-46. doi: 10.1177/87551225221092681. DOI: https://doi.org/10.1177/87551225221092681
Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine. 2022 Jan; 70(1): 5-13. doi: 10.1136/jim-2021-001952. DOI: https://doi.org/10.1136/jim-2021-001952
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal L, Lingvay I et al. Once-weekly semaglutide in adults with overweight or obesity without diabetes. New England Journal of Medicine. 2021 Mar; 384(11): 989–1002. doi: 10.1056/NEJMoa2032183. DOI: https://doi.org/10.1056/NEJMoa2032183
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV et al. Efficacy of once-weekly semaglutide vs placebo as adjunct to intensive behavioral therapy in adults with overweight or obesity: the STEP 3 randomized clinical trial. The Lancet. 2021 Mar; 397(10278): 971–984. doi: 10.1016/S0140-6736(21)00213-0. DOI: https://doi.org/10.1016/S0140-6736(21)00213-0
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016 Jul; 375(4): 311–322. doi: 10.1056/NEJMoa1603827. DOI: https://doi.org/10.1056/NEJMoa1607141
Xie Z, Yang S, Deng W, Li J, Chen J. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clinical Epidemiology. 2022 Jan: 1463-76. doi: 10.2147/CLEP.S391819. DOI: https://doi.org/10.2147/CLEP.S391819
Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. Journal of Managed Care & Specialty Pharmacy. 2022 Jul; 28(7): 740-52. doi: 10.18553/jmcp.2022.28.7.740. DOI: https://doi.org/10.18553/jmcp.2022.28.7.740
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. Journal of the American Medical Association. 2021 Apr; 325(14): 1403-13. doi: 10.1001/jama.2021.1831.
Pérez-Belmonte LM, Sanz-Cánovas J, García de Lucas MD, Ricci M, Avilés-Bueno B, Cobos-Palacios L et al. Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice. Frontiers in Endocrinology. 2022 Jun; 13: 851035. doi: 10.3389/fendo.2022.851035. DOI: https://doi.org/10.3389/fendo.2022.851035
Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024 Jul; 30(7): 2049-57. doi: 10.1038/s41591-024-02996-7. DOI: https://doi.org/10.1038/s41591-024-02996-7
Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes, Obesity and Metabolism. 2020 Aug; 22(8): 1263-77. doi: 10.1111/dom.14054. DOI: https://doi.org/10.1111/dom.14054
Rehman A, Saidullah S, Asad M, Gondal UR, Ashraf A, Khan MF et al. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity. Clinical Cardiology. 2024 May; 47(5): e24283. doi: 10.1002/clc.24283. DOI: https://doi.org/10.1002/clc.24283
Di Folco U, Vallecorsa N, Nardone MR, Pantano AL, Tubili C. Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. Acta Diabetologica. 2022 Oct; 59(10): 1287-94. doi: 10.1007/s00592-022-01936-6. DOI: https://doi.org/10.1007/s00592-022-01936-6
Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, Obesity and Metabolism. 2023 Feb; 25(2): 468-78. doi: 10.1111/dom.14890. DOI: https://doi.org/10.1111/dom.14890
Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Garvey WT et al. Effect of weekly subcutaneous semaglutide on weight loss in adults with overweight or obesity: the STEP 2 randomized clinical trial. Journal of the American Medical Association. 2021 Mar; 325(14): 1414–25. doi: 10.1001/jama.2021.1831. DOI: https://doi.org/10.1001/jama.2021.1831
Jódar Gimeno JE, Michelsen M, Polonsky W, Réa R, Sandberg A, Vilsbøll T et al. Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). 2020 Aug; 22(8): 1339-1347. doi: 10.1111/dom.14039. DOI: https://doi.org/10.1111/dom.14039
Klair N, Patel U, Saxena A, Patel D, Ayesha IE, Monson NR et al. What is best for weight loss? A comparative review of the safety and efficacy of bariatric surgery versus glucagon-like peptide-1 analogue. Cureus. 2023 Sep; 15(9). doi: 10.7759/cureus.46197. DOI: https://doi.org/10.7759/cureus.46197
Tzoulis P and Baldeweg SE. Semaglutide for weight loss: unanswered questions. Frontiers in Endocrinology. 2024 Jun; 15: 1382814. doi: 10.3389/fendo.2024.1382814. DOI: https://doi.org/10.3389/fendo.2024.1382814
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
